LexaGene Retains Wolf Greenfield Intellectual Property Law Firm
July 14 2021 - 7:45AM
LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (the
“
Company”), a molecular diagnostics company that
develops a fully automated rapid pathogen detection system, today
announced its strategic relationship with Wolf Greenfield, an
intellectual property (IP) law firm, specializing in patents,
licensing and royalty transactions, post-grant proceedings, and
trademark and copyrights.
Dr. Jack Regan, LexaGene’s CEO and Founder, stated, “As LexaGene
continues to grow, it’s important to not only protect but nurture
and grow the intellectual property assets of the Company. I’m very
pleased to have the nationally recognized expertise of Wolf
Greenfield on board for all of our strategic IP and licensing needs
moving forward.”
“The addition of Wolf Greenfield to our team will be important
as we continue expand our patent portfolio,” continued Dr. Regan.
“And combining the strengths of Wolf Greenfield for IP law and
licensing, along with Latham & Watkins for securities law,
gives us the capabilities of two of the most respected law firms in
the U.S. in their respective fields, as we continue to execute on
our growth objectives.”
Adding Wolf Greenfield to its representation portfolio
strengthens LexaGene’s positioning towards possibly listing its
common shares on the Nasdaq Capital Market.
The Company also announced that Dr. Regan will be speaking at
the “Access to Giving” investor conference on Thursday, July 15.
Access to Giving is a first-of-its-kind, virtual investor
conference, where companies from microcap up to mega-cap will have
the opportunity to present their company’s vision and participate
in meetings with qualified investors, all to benefit a range of
charities. To register or to learn more visit,
https://www.accesstogiving.com/. To listen to LexaGene’s
presentation register here:
https://www.webcaster4.com/Webcast/Page/2744/41999. The audio
recording will be posted to the LexaGene website, at a later
date.
To learn more about LexaGene and the MiQLab System or subscribe
to company updates, visit www.lexagene.com, or follow us on Twitter
or LinkedIn.
On Behalf of the Board of DirectorsDr.
Jack ReganChief Executive Officer &
Chairman
About Wolf GreenfieldFor nearly a century, Wolf
Greenfield has helped its clients protect their most valuable
intellectual property. With over 150 legal professionals based in
Boston and New York, the firm offers a full range of IP services,
including patent prosecution and litigation; post-grant
proceedings, including IPRs; opinions and strategic counseling;
licensing; intellectual property audits and due diligence;
trademark and copyright prosecution and litigation; and other
issues related to the commercialization of intellectual
property.
About LexaGene Holdings Inc.LexaGene is a
molecular diagnostics company that develops molecular diagnostic
systems for pathogen detection and genetic testing for other
molecular markers for on-site rapid testing in veterinary
diagnostics, food safety and for use in open-access markets such as
clinical research, agricultural testing, and biodefense. End-users
simply need to collect a sample, load it onto the instrument with a
sample preparation cartridge, enter sample ID and press ‘go.’ The
MiQLab™ system delivers excellent sensitivity, specificity, and
breadth of detection and can return results in approximately two
hours. The unique open-access feature is designed for custom
testing so that end-users can load their own real-time PCR assays
onto the instrument to target any genetic target of interest.
The TSX Venture Exchange Inc. has in no way
passed upon the merits of the proposed transaction and has neither
approved nor disapproved the contents of this press release.
Neither TSX Venture Exchange nor its Regulation Services Provider
(as that term is defined in the policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
This news release contains forward-looking information, which
involves known and unknown risks, uncertainties and other factors
that may cause actual events to differ materially from current
expectation. Important factors -- including the availability of
funds, the results of financing efforts, the success of technology
development efforts, the cost to procure critical parts,
performance of the instrument, market acceptance of the technology,
regulatory acceptance, and licensing issues -- that could cause
actual results to differ materially from the Company's expectations
as disclosed in the Company's documents filed from time to time on
SEDAR (see www.sedar.com). Readers are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date of this press release. The company disclaims
any intention or obligation, except to the extent required by law,
to update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
Corporate Contact:
Gail Winslow
Director of Corporate Marketing
gwinslow@lexagene.com
978.482.6237
ir@lexagene.com
800.215.1824
Lexagene (TSXV:LXG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Lexagene (TSXV:LXG)
Historical Stock Chart
From Jul 2023 to Jul 2024